Journal article
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
Abstract
BACKGROUND: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 …
Authors
Lonn E; Bosch J; Pogue J; Avezum A; Chazova I; Dans A; Diaz R; Fodor GJ; Held C; Jansky P
Journal
Canadian Journal of Cardiology, Vol. 32, No. 3, pp. 311–318
Publisher
Elsevier
Publication Date
March 2016
DOI
10.1016/j.cjca.2015.07.001
ISSN
0828-282X
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAngiotensin II Type 1 Receptor BlockersBenzimidazolesBiphenyl CompoundsBlood PressureCardiovascular DiseasesCholesterol, LDLDiureticsDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleGlobal HealthHumansHydrochlorothiazideIncidenceMaleMiddle AgedPopulation SurveillancePrimary PreventionRisk FactorsRosuvastatin CalciumTetrazolesTreatment Outcome